Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

SFDA Orders China Recall of GlaxoSmithKline Antibiotic

publication date: Jun 20, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
The SFDA has ordered GlaxoSmithKline to withdraw an antibiotic from China after trace elements of a banned substance were found in samples. The drug is amoxicillin and clavulanate potassium. The SFDA has been under pressure to take action after Taiwan and Hong Kong banned the drug two weeks ago. SFDA tests of the drug showed small amounts – the SFDA did not say how much – of an additive included in plastics to make them more flexible. From a larger perspective, the incident is one more skirmish in the long-running battle between China and the West over drug safety. More details....

Stock Symbol: (NYSE: GSK)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...